7 Best Peptides for Concussion

What to Know Before Choosing a Peptide for Concussion

No peptide is FDA-approved for treating concussion or post-concussion syndrome as of 2026. That is not a caveat buried at the bottom of this guide; it is the starting point, because it shapes how honest any useful discussion of this topic has to be. Conventional care still relies on rest, graded return-to-activity, and symptom monitoring, with no approved pharmacological options specifically targeting the multi-phase injury process that makes concussion so difficult to treat. That gap is what drives interest in peptide therapies and why this is an active area of off-label use, experimental research, and community discussion.

Every compound in this list earned its place by the same standard: people use it for concussion recovery, or are actively discussing using it. That standard does not require FDA approval, randomized controlled trial data, or commercial availability in the United States. Some entries have animal model data and a plausible mechanism. One has human trial data for a closely related condition. Some are known almost entirely through user-reported experience. Each compound's evidence is described honestly in its entry rather than used as a filter for inclusion. A compound with thin evidence that people genuinely use belongs here, with that thin evidence stated plainly.

The numbers in front of each entry give the list a spine. They are not a ranking. The order reflects how prominently each compound appears in published research and documented real-world use for concussion, not a recommendation of one compound over another. Someone who has read the whole guide and wants to turn that overview into a personalized plan will find that the MyPeptidePal app is built to do exactly that step.

1. Semax: For Neuroprotection and Cognitive Recovery

Semax is a synthetic heptapeptide derived from a fragment of ACTH, the adrenocorticotropic hormone, which means it was built by isolating a short stretch of a hormone the body already produces and refining it for neurological use. It was originally developed in Russia, where it has been approved as a nasal spray for certain cognitive and neurological indications, and it has since become one of the most discussed compounds in the concussion recovery community worldwide.

What draws people to Semax for concussion is the specificity of its mechanism. A concussion disrupts brain-derived neurotrophic factor, or BDNF, a protein that acts like fertilizer for neurons, supporting their survival, repair, and ability to form new connections. Semax increases cortical BDNF levels, with animal research showing a rise from roughly 142 to roughly 224 picograms per milligram of brain tissue within 72 hours of injury. It also activates protective mechanisms at the blood-brain barrier, the selective gateway that normally keeps harmful substances out of brain tissue but becomes leaky after concussion. Reducing oxidative stress and neuroinflammation are part of the same mechanism picture.

Of the compounds covered in this guide, Semax has the most developed concussion-specific research profile as of 2026. That said, the existing evidence comes from animal models. No completed human clinical trial has been published specifically for concussion treatment using Semax. What exists for human use is a combination of the compound's neurological approval history in Russia, off-label use through functional medicine clinics and compounding pharmacies in the United States, and a consistent pattern of user-reported benefit for cognitive symptoms. People most often report using it for brain fog, memory problems, and the cognitive slowing that characterizes post-concussion syndrome. The intranasal spray format is widely preferred over injection in community protocols, partly because it offers a practical non-injectable route and partly because intranasal delivery allows for relatively direct access to the central nervous system.

Semax is often used alongside Selank, a related synthetic peptide, for the anxiety and emotional dysregulation component of post-concussion syndrome. Because the two appear together frequently in community protocols, Selank has its own entry later in this guide.

2. BPC-157: For Blood-Brain Barrier Repair

BPC-157, which stands for Body Protection Compound-157, is a 15-amino-acid peptide originally derived from a protein found in gastric juice. It is probably the most commonly self-administered peptide for concussion and TBI recovery in the biohacking and sports recovery communities, frequently used alongside TB-500.

The reason BPC-157 gets attention specifically for concussion is the blood-brain barrier. After a concussion, the tight junction proteins that keep the BBB sealed, particularly ZO-1 and claudin-5, are disrupted, allowing inflammatory molecules and harmful substances to enter brain tissue and extend the secondary injury phase. BPC-157 acts primarily through the FAK-eNOS-VEGF pathway, a signaling chain that promotes repair of vascular tissue, stabilizes those tight junction proteins, and drives angiogenesis, the growth of new blood vessels to damaged areas. In practical terms, it targets one of the core biological problems that makes concussion recovery drag on.

The evidence supporting this mechanism comes from animal model research. No human clinical trial has been completed specifically for BPC-157 in concussion treatment. The preclinical data on BBB integrity is substantive enough that the mechanism is taken seriously, but the translation to human physiology has not been formally established. What fills that gap in practice is a large and vocal community of users. Accounts in TBI and post-concussion forums describe BPC-157 as genuinely helpful for brain fog, headaches, sleep problems, and the general sense that recovery has stalled. Some users describe significant improvement beginning around three to four weeks in, with more meaningful change over a longer arc.

Those accounts are not uniformly positive. A meaningful number of users report initial worsening, including increased anxiety, dizziness, nausea, and in some cases severe headaches, particularly in the early weeks. A few have described debilitating migraines appearing within hours of a first dose. The pattern of initial worsening before improvement is mentioned often enough in community discussion that it appears to be a real phenomenon rather than isolated bad luck, though no clinical data explains the mechanism behind it. That variance is worth weighing carefully for anyone considering this option.

BPC-157 is available as a research chemical from online suppliers and is offered at some functional medicine clinics. The quality concerns that apply to research-chemical peptides generally, including contamination and mislabeling risks, apply here.

3. TB-500: For Axonal Cytoskeletal Repair

TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid peptide that the body produces naturally and that plays a key role in how cells build and reorganize their internal scaffolding. In the context of concussion, that cellular scaffolding is central to one of the injury's defining features.

Diffuse axonal injury, a hallmark of concussion, involves the physical disruption of the cytoskeleton inside neurons, the structural protein framework that keeps the long projections of nerve cells intact and functional. TB-500 works primarily through G-actin sequestration, binding to a pool of actin that cells need to rebuild their structural networks. It activates a repair complex that drives actin polymerization at injury sites, which means it helps neurons reconstruct the damaged cytoskeleton rather than simply reducing inflammation around it. This makes TB-500 mechanistically specific to one of the defining biological features of concussion in a way that distinguishes it from most other compounds on this list. It also contributes to blood-brain barrier repair and angiogenesis through VEGF-mediated pathways, overlapping with BPC-157 in that dimension.

The evidence for TB-500 in concussion is preclinical. Animal studies demonstrate the tissue repair and axonal cytoskeleton mechanisms. No human clinical trial data has been published for this specific use. In real-world practice, TB-500 is most commonly used alongside BPC-157. The rationale people cite is complementary action: BPC-157 targeting the vascular and BBB component while TB-500 targets the structural axonal component. This combination is probably the most widely discussed self-administered protocol in TBI recovery communities.

TB-500 is broadly described in those communities as well-tolerated with fewer adverse events reported than BPC-157, though that assessment comes from self-reported experience rather than systematic monitoring. Athletes using TB-500 should verify its current status under applicable anti-doping frameworks before use, as Thymosin Beta-4 has historically been a monitored substance.

4. Cerebrolysin: For Neuroinflammation and Neurotrophic Support

Cerebrolysin is a peptide mixture derived from porcine brain proteins. Unlike the single synthetic compounds elsewhere on this list, it contains a range of neurotrophic peptide fragments that mimic the signaling behavior of the brain's own growth factors, including NGF, BDNF, CNTF, and GDNF. Those proteins play fundamental roles in neuronal survival, anti-inflammatory signaling, and the maintenance of neural circuits under stress. Cerebrolysin essentially delivers a concentrated set of neurotrophic signals to a brain under injury conditions.

It stands apart from the other entries in this guide because it has human clinical data, just not for concussion specifically. Cerebrolysin has been studied in randomized controlled trials for stroke and other neurological conditions, primarily in Eastern Europe and Asia, where it is an approved therapy. That clinical background gives it a different evidence foundation than compounds whose entire human-use record is anecdotal. The mechanism work in those stroke and neurodegenerative studies overlaps meaningfully with the neuroinflammation and neuroprotective targets relevant to concussion, which is why clinicians working in functional medicine sometimes reach for it when treating TBI patients with significant neuroinflammatory burden.

In concussion communities, Cerebrolysin is described by users who have tried it as one of the more potent options for reducing neuroinflammation, headaches, and the mental fog that can persist for months or years after a head injury. It is also consistently described as the hardest to obtain and the most expensive. In the United States it requires a compounding pharmacy and a prescription. Administration is typically via IV infusion or intramuscular injection, adding practical barriers beyond cost and sourcing. Some users note concerns about theoretical autoimmune risks that come with introducing foreign brain proteins, a question worth raising with a supervising physician. Those barriers, cost, access, and the need for physician involvement, mean it is far less commonly used than BPC-157 or Semax despite the more substantial clinical background behind it.

5. Selank: For Anxiety and Neuroinflammation in PCS

Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring immune peptide. Its primary concussion-relevant action is on neuroinflammation and the anxiety that frequently accompanies post-concussion syndrome, rather than on structural or vascular repair, which makes it functionally different from most of the other compounds on this list.

Post-concussion syndrome often carries an anxiety component that standard care addresses poorly. Selank works in part through TLR4-NF-kB pathway modulation, an anti-inflammatory signaling mechanism that reduces microglial priming, the sustained immune activation in brain tissue that perpetuates secondary injury. It also exerts enkephalin effects, meaning it influences the brain's endogenous anxiety-regulating chemistry in a way that has an anxiolytic, or anxiety-reducing, character without the sedating profile of pharmaceutical alternatives. The combination of anti-neuroinflammatory and anxiolytic action is what makes it a natural complement to Semax in community protocols, with Semax addressing cognitive recovery and BDNF while Selank targets the emotional and inflammatory dimensions of PCS.

The evidence for Selank in concussion is experiential rather than clinical. No completed human trial data has been published for this specific use as of 2026. What drives its inclusion here is consistent community discussion, particularly among people managing post-concussion syndrome, who report using it for anxiety, irritability, and neuroinflammatory symptoms that do not resolve on their own. Like Semax, it is available as a nasal spray, which is the format most users prefer.

6. CAQK: The Most Promising Emerging Discovery

CAQK is a tetrapeptide built from four amino acids: cysteine, alanine, glutamine, and lysine. It does not appear in most discussions of concussion peptides yet, and it is not something people are currently using, because it is not available anywhere for human use. It belongs in this guide because it represents the most scientifically compelling recent development in this space, and a complete picture of the peptide landscape for concussion would be genuinely incomplete without it.

Research published in EMBO Molecular Medicine in 2025 using mouse and pig models showed that CAQK travels to the brain after intravenous administration and accumulates specifically at injury sites. It does this by binding to extracellular matrix glycoproteins that are overexpressed only in damaged brain tissue, giving it a precision-targeting property that other compounds in this list lack entirely. At the injury site, it reduces neuroinflammation, lowers neuronal cell death, and shrinks lesion size, with no detectable toxicity or immune response observed in preclinical models.

What makes the mechanism particularly notable is the delivery route. The compound reaches the brain after IV administration without requiring invasive procedures or specialized delivery systems, removing a practical barrier that has held back other brain-targeted therapies. The research team has formed a company with the goal of seeking FDA authorization for a Phase I human trial, though no specific timeline has been set as of mid-2026. CAQK belongs on this list not because anyone is using it today, but because anyone following the evolving peptide landscape for concussion should know it exists and understand what it is designed to do.

7. CN-105: The Compound With Human Trial Data

CN-105 is an Apolipoprotein E mimetic peptide, meaning it is a short synthetic compound that replicates the biological activity of ApoE, a protein involved in inflammation regulation and lipid transport in the brain. It does not appear often in community discussions about concussion, and it is not available outside clinical trials. It earns a slot here because it is the only compound on this list with published human clinical trial data for a traumatic brain injury condition.

CN-105 has completed Phase 1 trials with a strong safety profile in both Western and Asian populations. It was studied in the CATCH trial, a Phase 2 randomized investigation in patients with intracerebral hemorrhage, a form of severe brain bleeding that involves overlapping neuroinflammatory and excitotoxic mechanisms with concussion. In that trial, IV administration was associated with improved 30-day functional outcomes, with an odds ratio of 2.69 compared to controls. A multicenter, randomized, double-blind, placebo-controlled trial is currently ongoing in Singapore for the same condition.

The critical distinction is that intracerebral hemorrhage is not the same as concussion, and these trials were not designed to test CN-105 for mild TBI specifically. The mechanistic overlap is real and worth noting, but direct extrapolation would be a stretch. CN-105 is not accessible to people seeking help outside a clinical trial setting. It is included here because any honest account of where the peptide field for TBI actually stands scientifically has to acknowledge that CN-105 is the most clinically advanced compound in the space, even if it remains out of reach for most people reading this guide.

How These Peptides Compare

Frequently Asked Questions

Are any peptides FDA-approved for concussion treatment?

No peptide is FDA-approved specifically for treating concussion or post-concussion syndrome as of 2026. The FDA has approved diagnostic tools for concussion assessment, including computerized neurocognitive tests and blood biomarker panels, but those are for evaluation, not treatment. All peptide use for concussion is currently off-label, investigational, or classified as research-chemical use, and the FDA has raised active safety concerns about unproven peptide chemicals sold for human use.

How do peptides for concussion differ from standard concussion care?

Standard concussion care centers on rest, graded return to activity, and monitoring for symptom progression, with no pharmacological treatment approved for the underlying neurometabolic injury. The peptides discussed in this guide target specific biological processes involved in that injury cascade, including blood-brain barrier disruption, axonal damage, neuroinflammation, and neurotrophic signaling deficits. Whether any of them produce meaningful benefit in humans for these specific mechanisms has not been established in completed clinical trials, though the mechanistic case for several compounds is grounded in real preclinical research.

Is it safe to use research-chemical peptides for concussion recovery?

No established clinical safety profile exists for these compounds specifically in concussion recovery. General concerns for research-chemical peptides include contamination, mislabeling, dosing inaccuracy, and the absence of sterility guarantees. Beyond sourcing quality, potential adverse effects span neurological, gastrointestinal, and immune categories, and some users report significant worsening of symptoms, particularly with BPC-157. Anyone considering these compounds should do so under physician supervision rather than through self-administration without medical oversight.

How long do people typically report it takes to see results?

User-reported timelines vary considerably by compound and by the severity and age of the injury. For BPC-157, the most commonly reported pattern in community accounts is minimal or mixed effects in the first two to three weeks, with more consistent improvement beginning around week three or four and meaningful change over months rather than days. These are community-reported observations, not clinical findings, and some users report rapid improvement while others report no benefit at all. No validated clinical timeline exists for any of these compounds in concussion recovery.

Can these peptides be combined?

The BPC-157 and TB-500 combination is the most commonly discussed pairing in TBI recovery communities, based on the complementary logic of targeting vascular and BBB repair alongside axonal structural repair. Semax and Selank are similarly often discussed together, with Semax targeting cognitive recovery and Selank addressing anxiety and neuroinflammation. Whether combinations produce additive or synergistic effects has not been studied in controlled research for concussion, and all decisions about combining compounds carry compounded uncertainty that should involve a knowledgeable physician.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for concussion in one place.